目的 研究長春胺膠囊聯(lián)合倍他司汀治療突發(fā)神經(jīng)性耳聾的臨床療效。方法 納入太原鋼鐵（集團）有限公司總醫(yī)院2021年1月—2022年6月接診的300例突發(fā)神經(jīng)性耳聾患者，按照數(shù)字表法隨機分為治療組和對照，每組各150例。對照組口服鹽酸倍他司汀口服液，10 mg/次，3次/d。治療組在對照組基礎上口服長春胺緩釋膠囊，30 mg/次，2次/d。兩組均治療14 d。觀察兩組患者臨床療效，比較治療前后兩組患者聽力閾值，C反應蛋白（CRP）水平，血流流變學指標高切黏度、低切黏度、全血黏度與纖維蛋白原。結(jié)果 治療后，治療組患者總有效率顯著高于對照組（97.33%vs 85.33%，P<0.05）。治療后，兩組患者在1、2、4 kHz頻率點的聽力閾值顯著低于治療前（P<0.05），且治療組明顯低于對照組（P<0.05）。治療后，兩組高切黏度、低切黏度、全血黏度與纖維蛋白原均明顯低于治療前（P<0.05），且治療組患者低于對照組（P<0.05）。治療后，兩組患者CRP水平均明顯低于治療前（P<0.05），且治療組患者低于對照組（P<0.05）。結(jié)論 長春胺聯(lián)合倍他司汀方案可更好改善突發(fā)神經(jīng)性耳聾患者的血液黏稠度與CRP水平，增強細胞免疫功能，提高臨床療效。

Objective To study the clinical efficacy of vincamine combined with betahistine in treatment of sudden deafness. Methods Patients (300 cases) with sudden deafness in General Hospital of Taiyuan Iron and Steel (Group) Co., Ltd. from January 2021 to June 2022 were divided into treatment group and control group according to the numerical table method, 150 cases in each group. Patients in the control group were po administered with Betahistine Hydrochloride Oral Solution, 10 mg/time, three times daily. Patients in the treatment group were po administered with Vincamine Sustained Release Capsules on the basis of the control group, 30 mg/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, and the hearing threshold, CRP level, hemorheology indexes high shear viscosity, low shear viscosity, whole blood viscosity, and fibrinogen in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (97.33% vs 85.33%, P< 0.05). After treatment, the hearing threshold at 1 kHz, 2kHz, and 4kHz in two groups were significantly lower than those before treatment (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, high shear viscosity, low shear viscosity, whole blood viscosity, and fibrinogen in two groups were significantly lower than those before treatment (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the CRP levels in two groups were significantly lower than before treatment (P < 0.05), and CRP levels in the treatment group patients were lower than that in the control group (P< 0.05). Conclusion Vincristine combined with betastine can better improve blood viscosity and CRP level, enhance cellular immune function and improve clinical efficacy in patients with sudden neurotic deafness.

R971

山西省衛(wèi)生計生委科研課題計劃項目（2018056）